

## State of Oklahoma **Oklahoma Health Care Authority** PCSK9 Inhibitor Prior Authorization Form

PCSK9 IIIIIbitoi Piloi Autiloii Zatioii i oilii	
	Pharmacy Section
Me	mber Name: Date of Birth: Member ID#: nrmacy NPI: Pharmacy Phone: Pharmacy Fax:
Pn	Pharmacy NPI: Pharmacy Phone: Pharmacy Fax:
PII Dr	ecribor NDI: Proscribor Namo: Specialty:
Pr	scriber NPI Prescriber Name Specialty Specialty
NE	C: Fill Quantity: Day Supply:
Ha	Printing NPIPharmacy FixPharmacy Name:Pharmacy Name:
Ph	rmacist Signature: Date:
	Prescriber Section
ΛII	information must be provided and SoonerCare may verify through further requested documentation. The
	mber's prescription claim history will be reviewed prior to approval.
	Initial Authorization (Initial approval will be for the duration of 3 months):
	Please indicate member's diagnosis:
	Homozygous familial hypercholesterolemia (HoFH) confirmed by 1 of the following:
	☐ Untreated total cholesterol >500mg/dL and at least 1 of the following:
	Documented evidence of definite HeFH in both parents; or
	☐ Presence of tendinous/cutaneous xanthoma prior to age 10 years
	☐ Documented functional mutation(s) in both LDL receptor alleles via genetic testing**
	(**Please note if this option is selected, genetic testing results must be submitted with the prior authorization request)
	☐ Primary hyperlipidemia
	☐ Established cardiovascular disease (CVD) (to reduce the risk of myocardial infarction, stroke, coronary
	revascularization, and unstable angina requiring hospitalization). Please provide supporting diagnoses/conditions
	and dates of occurrence signifying established CVD:
	Diagnosis/condition: Date of occurrence: Date of occurrence:
_	Diagnosis/condition: Date of occurrence:
2.	Please specify the member's current statin therapy:
	a) Drug Name: Dose: Duration of treatment: Duration of treatment: Dose: Duration of treatment: Duration of treatment: Dose: Dose: Duration of treatment: Dose:
	c) If "Yes", please provide member's LDL-C level following 12 weeks of statin therapy:
	SoonerCare claims analysis will be conducted to verify adherence.
	d) If member is statin intolerant due to myalgia, provide creatine kinase (CK) labs verifying rhabdomyolysis.
	Members with myalgia not confirmed by CK labs must have at least 2 trials of lower dose statin therapy or failure of
	intermittent dosing.
3.	Member's baseline LDL-C: Current LDL-C: Goal LDL-C:
4.	How will this medication be used? ☐ Monotherapy ☐ Adjunct to statin therapy, diet, and exercise
5.	Has the member been counseled on proper administration and storage of PCSK9 therapy? Yes No
E۵	Continued Authorization:
1.	Has member been compliant with PCSK9 Inhibitor treatment? Yes No
	Has PCSK9 Inhibitor treatment been effective for this member? Yes No
	Please provide a recent LDL-C level for this member:  Date taken:
	•
Pr	scriber Signature: Date:
By	signature, the physician confirms the criteria information above is accurate and verifiable in patient records. Please do not send in chart is. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.
HOL	s. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.
Member (Patient) Section For Initial Authorization Only	
Ple	ase have the member initial after each line, fill in all blanks, and sign at the bottom.
	I understand this medicine must be injected. Initials:
2.	I understand I must give myself a shot every week(s). Initials:
	I understand this medication must be kept in the refrigerator. Initials:
	I will not leave this medication in the car or anywhere it would get hot. Initials:
	I understand this medication will not be replaced if I leave it out of the refrigerator. Initials:
Me	mber Signature: Date:

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

> University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit Fax: 1-800-224-4014

Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE
This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.